Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
Phase 1
Completed
- Conditions
- SARS-CoV-2SARS-CoV
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Vaccine Company, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT05938075
- Locations
- ๐ฟ๐ฆ
Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Academic Hospital, Johannesburg, Gauteng, South Africa
๐ฟ๐ฆHIV and other Infectious Diseases Research Unit (HIDRU), South African Medical Research Council, Botha's Hill, Kwa-Zulu Natal, South Africa
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Vaccine Company, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT05870839
- Locations
- ๐บ๐ธ
University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States
๐บ๐ธThe Hope Clinic of Emory University, Decatur, Georgia, United States
๐บ๐ธUniversity of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath